Figure 5
Pharmacokinetic properties and antitumoral activity of scTRAIL and scFv–scTRAIL. (a) Reduced elimination of scFv–scTRAIL from circulation. scTRAIL and scFv–scTRAIL were detected by ELISA in serum samples obtained at the indicated time points after i.v. injection into Balb/c mice. For each protein three mice were treated. Significant differences between both proteins were marked by asterisks. (b) Antitumoral activity in a xenograft tumor model – local treatment. NMRI nu/nu mice were injected s.c. with 3 × 106 human colon carcinoma Colo205 cells. Treatment started when tumors reached about 25 mm2 (8 days after inoculation). Mice received four daily s.c. injections of 1 nmol of the corresponding proteins beginning day 0. n=7 tumors per treatment group; symbols, mean of tumor volumes; bars, S.E.M. Individual tumor sizes at day 11 with bars indicating the mean are shown on the right. (c) Antitumoral activity in a xenograft tumor model – systemic treatment. 3 × 106 Colo205 cells were s.c. inoculated at the left and right dorsal site of NMRI nu/nu mice. Treatment started when tumors reached about 25 mm2 (5 days after inoculation). Mice received eight daily i.v. injections of 1 nmol of the corresponding proteins beginning at day 0. n=8 tumors per treatment group; symbols, mean of tumor volumes; bars, S.E.M. Individual tumor sizes at day 19 with bars indicating the mean are shown on the right
